Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients

29 Oct 2013

Abstract excerpt

PURPOSE: KRAS wild-type status is an imperfect predictor of sensitivity to anti-EGF receptor (EGFR) monoclonal antibodies in colorectal cancer, motivating efforts to identify novel molecular aberrations driving RAS. This study aimed to build a quantitative readout of RAS pathway activity to (i) uncover molecular surrogates of RAS activity specific to colorectal cancer, (ii) improve the prediction of cetuximab...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Colorectal Cancer Treatments and Studies
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24170544
DOI: 10.1158/1078-0432.ccr-13-1943

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in PatientsPMID 24170544Read ↗

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.Semantic proximity Read ↗

The genomic landscape of response to EGFR blockade in colorectal cancer.Semantic proximity Read ↗

Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitorsSemantic proximity Read ↗

Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.Semantic proximity Read ↗

Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants.Semantic proximity Read ↗

KRAS Mutation Status as a Prognostic Marker and Predictor of Therapy Response in Colorectal Cancer: an NCDB Analysis.Semantic proximity Read ↗

Cancer modeling in colorectal organoids reveals intrinsic differences between oncogenic <i>RAS</i> and <i>BRAF</i> variantsSemantic proximity Read ↗

Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential.Semantic proximity Read ↗

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.Semantic proximity Read ↗

Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patientsSemantic proximity Read ↗

Profiling the kinome in oncogenic RAS mutant cellsSemantic proximity Read ↗

Ras in digestive oncology: from molecular biology to clinical implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.